Sana Biotechnology, Inc. has announced a strategic collaboration with Mayo Clinic to expedite the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for patients with type 1 diabetes (T1D). This partnership aims to enhance clinical protocols and operational workflows for SC451, which is designed to provide long-term glucose control through a single administration of pancreatic islet cells, eliminating the need for ongoing insulin therapy or immunosuppression.

The collaboration leverages Mayo Clinic’s extensive expertise in transplant medicine and immunology to refine the delivery and management of SC451 across diverse clinical settings. Key initiatives will focus on optimizing product handling, surgical techniques, and clinical trial design, including biomarker identification for patient selection. Notably, preliminary data show that transplanted islet cells using Sana’s hypoimmune platform can survive and function without immunosuppression for over a year, indicating a significant therapeutic potential for transforming T1D management.

This partnership not only accelerates the timeline for SC451’s clinical trials—expected to initiate as early as this year—but also sets a precedent for future collaborations between biotech firms and clinical institutions. By combining resources and expertise, this collaboration could lead to scalable solutions for T1D, potentially reshaping treatment paradigms and enhancing patient outcomes in the field of cell therapy and immunology.

Source: globenewswire.com